Mirova’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.02M Buy
95,933
+77,657
+425% +$6.21M 0.24% 108
2025
Q4
$1.74M Sell
18,276
-1,918
-9% -$188K 0.25% 68
2025
Q3
$1.97M Hold
20,194
0.28% 68
2025
Q2
$2.17M Sell
20,194
-2,136
-10% -$216K 0.31% 65
2025
Q1
$2.25M Sell
22,330
-2,772
-11% -$279K 0.41% 56
2024
Q4
$2.24M Sell
25,102
-2,661
-10% -$234K 0.39% 56
2024
Q3
$2.33M Buy
27,763
+21,026
+312% +$1.66M 0.4% 57
2024
Q2
$519K Hold
6,737
0.09% 91
2024
Q1
$461K Buy
+6,737
New +$433K 0.08% 86
2023
Q3
Sell
-3,269
Closed -$177K 130
2023
Q2
$177K Sell
3,269
-5,431
-62% -$284K 0.03% 125
2023
Q1
$435K Buy
+8,700
New +$410K 0.06% 116
2021
Q4
Sell
-4,459
Closed -$193K 181
2021
Q3
$193K Buy
4,459
+393
+10% +$17.4K 0.02% 147
2021
Q2
$173K Sell
4,066
-285
-7% -$12K 0.02% 149
2021
Q1
$168K Buy
4,351
+702
+19% +$26.6K 0.02% 148
2020
Q4
$131K Buy
3,649
+2,608
+251% +$94K 0.02% 135
2020
Q3
$40K Buy
1,041
+810
+351% +$31.2K 0.01% 138
2020
Q2
$8K Hold
231
﹤0.01% 161
2020
Q1
$8K Hold
231
﹤0.01% 156
2019
Q4
$10K Buy
+231
New +$9.67K ﹤0.01% 164

Other funds holding BSX

Mirova's BSX Position: Q1 2026 in Review

Mirova increased its Boston Scientific (BSX) stake by 425% in Q1 2026, buying an estimated $6.21M and bringing the position to 95,933 shares worth $6.02M. The position accounts for 0.24% of the portfolio, ranked #108.

Mirova first reported a position in BSX in Q4 2019 and has held it in 19 quarters since. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Mirova held 95,933 shares of Boston Scientific worth $6.02M as of Q1 2026.
  • Mirova bought 77,657 Boston Scientific shares in Q1 2026, an estimated $6.21M.
  • Boston Scientific made up 0.24% of Mirova's portfolio in Q1 2026, its #108 holding.
  • Mirova first reported a position in Boston Scientific in Q4 2019 and has held it in 19 quarters since.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Mirova's 13F filing for Q1 2026, filed 14 May 2026.